GNS constructs immuno-inflammation model with BMS trial data
A computer model that can support virtual clinical trials in the field of immuno-inflammation is the goal of a new collaboration between Bristol-Myers Squibb (BMS) and US-based healthcare analytics company GNS Healthcare, according to PharmaTimes.
No financial terms were disclosed on the tie-up, under which GNS will take clinical and molecular information from a BMS clinical trial and will use its supercomputer-driven REFS (reverse-engineering and forward-simulation) platform to construct a comprehensive inflammation disease model “directly from the raw data.”
These patient data comprise genetic information, gene expression levels, specific blood markers and clinical outcomes that can help BMS to identify key molecular mechanisms and biomarkers in immuno-inflammation.
The resulting disease model will support virtual clinical trials that simulate the clinical impact of inhibiting various drug targets and help to predict novel molecular targets for combating immuno-inflammation, effective in specific types of patients, GNS noted.
“This is the first step in building a significantly advanced in silico research paradigm that may enable development of new therapies based directly on human data, and address the needs of patients with particular genetics and molecular phenotypes, ultimately enabling the optimization of individualized patient outcomes,” commented Dr. Iya Khalil, executive vice president and co-founder of GNS Healthcare.